Fluorine-18 labeled rhodamine derivatives for imaging with positron emission tomography
The present invention is directed toward novel fluorine-18 labeled rhodamine dye derivatives and methods of making the same. The present invention is also directed toward methods of using novel fluorine-18 labeled rhodamine dye derivatives as positron emission tomography imaging agents and myocardial perfusion imaging agents.
1. A compound comprising an 18 F labeled rhodamine derivative according to formula I:
wherein
R 2 and R 3 are alkyl;
R 1 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen;
A 1 is carbon or nitrogen, if A 1 is nitrogen, then R 6 is absent;
R 15 is CH 2 CH 2 OCH 2 CH 2 18 F;
and
A − is an anion.
2. The compound of claim 1 , wherein the compound is
3. The compound of claim 1 , wherein R 2 and R 3 are alkyl; R 1 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen; and A 1 is carbon.
4. The compound of claim 3 , wherein R 2 is ethyl.
5. The compound of claim 3 , wherein R 3 is ethyl.
6. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
7. A method of obtaining a positron emission image of a portion of a mammal, comprising the steps of:
administering to a mammal a compound of claim 1 ; and
acquiring a positron emission image of a portion of a mammal
wherein said portion of a mammal is the myocardium.
8. The method of claim 7 wherein the mammal is a human.
9. A method of imaging myocardial perfusion comprising:
administering to a patient a compound of claim 1 or 6 ; and
scanning the patient using diagnostic imaging.
10. The compound of claim 1 , wherein the compound of formula (I) is a myocardial positron imagining agent.
11. The compound of claim 1 , wherein R 1 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen; R 2 and R 3 are ethyl; and A l is carbon.